Tag: Claudin18.2

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

Two phase 1 clinical trials will evaluate EO-3021 (also known as SYSA1801), a differentiated, clinical-stage antibody-drug conjugate (ADC) targeting Claudin 18.2 (a specific isoform of Claudin 18 that is normally expressed in gastric epithelial cells)*, in combination with ramucirumab (Cyramza®;Eli Lilly and Company/ImClone Systems) , a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab (Jemperli®; GSK), a PD-1 inhibitor, in the front-line setting. Initiate dosing in the combination portion of the Phase 1 trial is expected by year-end 2024. [